NEW YORK (GenomeWeb News) – PharmiGene said today that the Department of Health in Taiwan has granted the firm approval to market its PG 1502 DNA detection kit on the island.
The test is used to identify patients at greater risk for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening adverse drug reactions. Carbamazepine is an anti-convulsant and mood-stabilizing drug used to treat epilepsy, biopolar disorder, and schizophrenia, among other conditions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.